News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
120,226 Results
Type
Article (8316)
Company Profile (56)
Press Release (111853)
Multimedia
Podcasts (37)
Webinars (2)
Section
Business (55105)
Career Advice (213)
Deals (17623)
Drug Delivery (35)
Drug Development (10333)
Employer Resources (20)
FDA (1968)
Job Trends (2954)
News (67935)
Policy (3940)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (1)
2027 Genetown Digital (1)
2027 NextGen (2)
2027 Pharm Country Digital (1)
40 Under 40 (1)
Academia (295)
Accelerated approval (5)
ADA (6)
Adcomms (2)
Allergies (18)
Alliances (8598)
ALS (20)
Alzheimer's disease (195)
Antibody-drug conjugate (ADC) (133)
Approvals (2058)
Artificial intelligence (144)
ASCO (33)
Autoimmune disease (98)
Automation (17)
Bankruptcy (84)
Belgium (10)
Best Places to Work (2100)
BIO (17)
Biologics (6)
BIOSECURE Act (2)
Biosimilars (42)
BioSpace Insights (29)
Biotechnology (39)
Bispecific (4)
Bladder cancer (14)
Brain cancer (22)
Breast cancer (121)
Cancer (1023)
Cardiovascular disease (82)
Career advice (199)
Career pathing (8)
CAR-T (93)
CDC (6)
CDMO (44)
Celiac Disease (1)
Cell therapy (203)
Cervical cancer (15)
Clinical research (9175)
Collaboration (510)
Commercialization (10)
Company closure (4)
Compensation (223)
Complete response letters (11)
COVID-19 (406)
CRISPR (19)
CRO (1)
C-suite (403)
Cystic fibrosis (14)
Data (1460)
Denatured (9)
Depression (32)
Dermatology (23)
Diabetes (68)
Diagnostics (1444)
Digital health (10)
Diversity (3)
Diversity, equity & inclusion (2)
Drug discovery (98)
Drug pricing (17)
Drug shortages (4)
Duchenne muscular dystrophy (76)
Earnings (17943)
Editorial (11)
Employer branding (3)
Employer resources (19)
ESMO (40)
Events (13257)
Executive appointments (343)
Eye disease (1)
FDA (2648)
Fibrodysplasia Ossificans Progressiva (1)
Fragile X (1)
Friedreich's ataxia (11)
Frontotemporal dementia (9)
Funding (482)
Gene editing (57)
Generative AI (6)
Gene therapy (153)
GLP-1 (252)
Government (452)
Guidances (160)
Healthcare (2704)
Hematology (24)
HIV (45)
Huntington's disease (8)
IgA nephropathy (38)
Immunology and inflammation (96)
Immuno-oncology (34)
Indications (38)
Infectious disease (474)
Inflammatory bowel disease (46)
Inflation Reduction Act (6)
Influenza (18)
Intellectual property (90)
Interviews (19)
IPO (3473)
IRA (8)
Job creations (867)
Job search strategy (173)
JPM (18)
Kidney cancer (15)
Kidney disease (34)
Labor market (29)
Layoffs (166)
Leadership (8)
Legal (1137)
Licensing (16)
Liver cancer (18)
Longevity (9)
Lung cancer (174)
Lung diease (4)
Lymphoma (66)
Machine learning (15)
Management (7)
Manufacturing (275)
Marketing (5)
MASH (46)
Medical device (2123)
Medtech (2159)
Mergers & acquisitions (15189)
Metabolic disorders (307)
mRNA (58)
Multiple sclerosis (52)
Multispecific (2)
NASH (1)
Netherlands (3)
Neurodegenerative disease (98)
Neuropsychiatric disorders (37)
Neuroscience (502)
Neurotech (1)
NextGen: Class of 2026 (1141)
Non-profit (311)
Now hiring (22)
Obesity (179)
Opinion (70)
Ovarian cancer (48)
Pain (61)
Pancreatic cancer (46)
Parkinson's disease (50)
Partnered (9)
Patents (142)
Patient recruitment (112)
Patient selection (13)
Peanut (5)
People (13361)
Peptides (1)
Pharmaceutical (9)
Pharmacy benefit managers (1)
Phase 1 (2972)
Phase 2 (4205)
Phase 3 (3235)
Pipeline (2566)
Policy (38)
Postmarket research (165)
Preclinical (1257)
Press Release (4)
Prostate cancer (37)
Psychedelics (17)
Radioligand (1)
Radiopharmaceuticals (81)
Rare diseases (283)
Real estate (1115)
Recruiting (11)
Regenerative medicine (2)
Regulatory (3255)
Reports (15)
Research institute (292)
Resumes & cover letters (30)
Rett syndrome (19)
RNA editing (9)
RSV (6)
Schizophrenia (43)
Series A (115)
Series B (58)
Service/supplier (1)
Sickle cell disease (13)
Special edition (8)
Spinal muscular atrophy (23)
Sponsored (7)
Startups (1097)
State (1)
Stem cells (1)
Stomach cancer (4)
Substance use disorders (1)
Supply chain (23)
Tariffs (11)
The Weekly (28)
Vaccines (171)
Venture capital (52)
Weight loss (105)
Women's health (47)
Women in leadership (1)
Worklife (3)
Date
Today (30)
Last 7 days (134)
Last 30 days (480)
Last 365 days (5852)
2026 (4789)
2025 (5673)
2024 (6412)
2023 (7367)
2022 (9628)
2021 (10568)
2020 (9512)
2019 (7115)
2018 (5804)
2017 (5848)
2016 (5244)
2015 (6296)
2014 (4335)
2013 (3258)
2012 (3685)
2011 (3818)
2010 (3486)
Location
Africa (130)
Alabama (10)
Arizona (62)
Arkansas (1)
Asia (7504)
Australia (945)
California (3607)
Canada (936)
China (310)
Colorado (146)
Connecticut (107)
Delaware (76)
Europe (16723)
Florida (400)
Georgia (93)
Hawaii (2)
Idaho (8)
Illinois (180)
India (15)
Indiana (171)
Iowa (1)
Japan (164)
Kansas (22)
Kentucky (10)
Louisiana (16)
Maine (5)
Maryland (257)
Massachusetts (1966)
Michigan (59)
Minnesota (99)
Mississippi (1)
Missouri (27)
Montana (1)
Nebraska (2)
Nevada (12)
New Hampshire (16)
New Jersey (712)
New Mexico (1)
New York (531)
North Carolina (403)
North Dakota (2)
Northern California (1853)
Ohio (129)
Oklahoma (3)
Oregon (11)
Pennsylvania (440)
Puerto Rico (6)
Rhode Island (10)
South America (208)
South Carolina (19)
Southern California (1442)
Tennessee (124)
Texas (366)
United States (10058)
Utah (51)
Vermont (2)
Virginia (58)
Washington D.C. (7)
Washington State (266)
West Virginia (3)
Wisconsin (38)
120,226 Results for "sofie sofie biosciences acquired zevacor".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GE HealthCare to Acquire SOFIE Biosciences, Establishing a ‘Final Mile’ Footprint for PET Radiopharmaceutical Supply in the U.S.
October 5, 2026
·
8 min read
Press Releases
Allotera Therapeutics Announces Opening of Minimal Residual Disease Cohort in the Pivotal T-RRex Study of Sofi-cel
September 23, 2026
·
3 min read
Press Releases
SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study for Pancreatic Cancer
February 11, 2026
·
3 min read
Press Releases
SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study
December 29, 2025
·
5 min read
Press Releases
SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement
October 2, 2025
·
6 min read
Genetown
Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland
Life Molecular Imaging and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE’s radiopharmaceutical manufacturing site located in Cleveland, Ohio.
April 5, 2024
·
5 min read
Press Releases
NEURELIS TO PARTICIPATE IN SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
November 11, 2025
·
7 min read
Drug Development
First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [18F]FAPI-74 in its US Clinical Trial of flourine-18 labeled Fibroblast Activation Protein Inhibitor (FAPI).
May 12, 2023
·
2 min read
Business
RLS and Sofie Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients
RLS, Inc., the third-largest nuclear medicine pharmacy network in the US, and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, entered into a strategic partnership for RLS to distribute SOFIE nuclear medicine doses for patients.
June 21, 2023
·
2 min read
Drug Development
First Patient Imaged in SOFIE’s FAPI Phase II trial
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [ 68 Ga]FAPI-46 at NYU Langone in its US Clinical Trial of Fibroblast Activation Protein Inhibitor (FAPI).
October 13, 2022
·
3 min read
1 of 12,023
Next
